SynthesisEndocrinology, diabetes & metabolism2026
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Synthesis in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial weight loss in adults with obesity. Given ethnic differences in obesity phenotype and cardiometabolic risk, this systematic review and meta-analysis compared tirzepatide's efficacy and safety between Asian and non-Asian adults without diabetes.
methodsThis PROSPERO-registered review (CRD420261361351) searched PubMed, Scopus, Web of Science and ClinicalTrials.gov through 15 March 2026. Phase 3 SURMOUNT randomised, placebo-controlled trials were classified as Asian (100% Asian participants) or predominantly non-Asian (< 25% Asian participants). The primary outcome was the percentage change in body weight. Secondary outcomes included absolute weight change, body mass index (BMI), waist circumference, weight loss thresholds (≥ 5%, ≥ 10%, ≥ 15%) and adverse events. Random-effects meta-analyses and meta-regression were performed.
resultsFive trials (six comparisons; N = 4022) were included: two Asian (SURMOUNT-CN, SURMOUNT-J; n = 148 tirzepatide-treated) and four predominantly non-Asian. Tirzepatide 15 mg/maximum tolerated dose produced an 18.04% greater reduction in body weight versus placebo (95% CI -19.86 to -16.22; p < 0.00001, I
conclusionsTirzepatide provides clinically meaningful weight reduction, with broadly similar relative percentage efficacy across Asian and non-Asian trial populations. These exploratory, indirect findings do not establish ethnic equivalence and require confirmation in adequately powered, ethnicity-stratified trials. REGISTRATION: The meta-analysis was registered in PROSPERO under the registration number CRD420261361351. The review protocol summary is available on the PROSPERO website.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.